HKD 1.11
(14.43%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 438.33 Million CNY | 73.81% |
2022 | 261.42 Million CNY | 66.24% |
2021 | 157.26 Million CNY | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 133.25 Thousand HKD | -0.15% |
2024 Q1 | 134.4 Thousand HKD | -99.95% |
2023 Q1 | 98.35 Thousand HKD | -99.93% |
2023 Q4 | 276.81 Million HKD | 186828.03% |
2023 Q3 | 148.08 Thousand HKD | -99.92% |
2023 Q2 | 175.26 Million HKD | 178087.76% |
2023 FY | 454.37 Million CNY | 73.81% |
2022 Q2 | 125.75 Million HKD | 0.0% |
2022 FY | 261.42 Million CNY | 66.24% |
2022 Q4 | 135.4 Million HKD | 0.0% |
2021 FY | 157.26 Million CNY | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Uni-Bio Science Group Limited | 325.05 Million HKD | -34.852% |
CK Life Sciences Int'l., (Holdings) Inc. | 739.25 Million HKD | 40.706% |